Suardi, Gabriela Aparecida Marcondes 
; Wiezel, Cláudia Emília Vieira ; Tirapelli, Daniela Pretti da Cunha ; Ramos, Ester Silveira ; Almeida, Vania de; Siciliano, Velia; Gerson, Stanton; Weiss, Ron; Fontes, Aparecida Maria
Source: Resumos (e-Book ). Conference titles: International Congress of the Brazilian Genetics Society. Unidade: FMRP
Subjects: DOENÇAS METABÓLICAS, ENZIMAS, LINHAGEM CELULAR, DNA RECOMBINANTE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SUARDI, Gabriela Aparecida Marcondes et al. Stable and cost-effective production of GCASE-OPT using a low MOI lentiviral approach for enzyme replacement therapy in gaucher disease: development of L20_HEF1A_GBA-OPT-R534H, a stable human cell line. 2024, Anais.. Ribeirão Preto: Sociedade Brasileira de Genética (SBG), 2024. Disponível em: https://www.sbg.org.br/admin/files/book/book_bcovOe2cEJzf.pdf. Acesso em: 28 jan. 2026.APA
Suardi, G. A. M., Wiezel, C. E. V., Tirapelli, D. P. da C., Ramos, E. S., Almeida, V. de, Siciliano, V., et al. (2024). Stable and cost-effective production of GCASE-OPT using a low MOI lentiviral approach for enzyme replacement therapy in gaucher disease: development of L20_HEF1A_GBA-OPT-R534H, a stable human cell line. In Resumos (e-Book ). Ribeirão Preto: Sociedade Brasileira de Genética (SBG). Recuperado de https://www.sbg.org.br/admin/files/book/book_bcovOe2cEJzf.pdfNLM
Suardi GAM, Wiezel CEV, Tirapelli DP da C, Ramos ES, Almeida V de, Siciliano V, Gerson S, Weiss R, Fontes AM. Stable and cost-effective production of GCASE-OPT using a low MOI lentiviral approach for enzyme replacement therapy in gaucher disease: development of L20_HEF1A_GBA-OPT-R534H, a stable human cell line [Internet]. Resumos (e-Book ). 2024 ;[citado 2026 jan. 28 ] Available from: https://www.sbg.org.br/admin/files/book/book_bcovOe2cEJzf.pdfVancouver
Suardi GAM, Wiezel CEV, Tirapelli DP da C, Ramos ES, Almeida V de, Siciliano V, Gerson S, Weiss R, Fontes AM. Stable and cost-effective production of GCASE-OPT using a low MOI lentiviral approach for enzyme replacement therapy in gaucher disease: development of L20_HEF1A_GBA-OPT-R534H, a stable human cell line [Internet]. Resumos (e-Book ). 2024 ;[citado 2026 jan. 28 ] Available from: https://www.sbg.org.br/admin/files/book/book_bcovOe2cEJzf.pdf
